AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02744443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Study NCT02744443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05698082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining with anti-FOS
Description: The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
Study NCT03187938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing of Alkaline Phosphatase Levels
Description: Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
Study NCT03922386 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: XFINE leads
Description: Pacemaker subjects with at least one XFINE passive lead
Study NCT03622489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: mentioned above
Study NCT03622489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: mentioned above
Study NCT03622489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyrone
Description: mentioned above
Study NCT03622489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: mentioned above
Study NCT01989403 — intervention group
Intervention type: OTHER
Intervention: herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation
Study NCT01528111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX7101 (0.125%)
Description: Subjects will receive 0.125% LX7101
Study NCT01528111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX7101 (0.25%)
Description: Subjects will receive 0.25% LX7101
Study NCT01528111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX7101 Vehicle
Description: Subjects will receive vehicle
Study NCT04315675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery Intervention
Description: The participant listens to a selected Guided Imagery for 21 consecutive days.
Study NCT04315675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Power Intervention
Description: The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
Study NCT04315675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Guided Imagery and Cognitive Power Intervention
Description: The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
Study NCT03329911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU Avastin®
Description: 100 mg/4 mL
Study NCT03329911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1706
Description: 100 mg/4 mL
Study NCT03329911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m²
Study NCT03329911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m²
Study NCT03329911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: target area under the curve \[AUC\] 6 mg/mL•minute
Study NCT03329911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: target area under the curve \[AUC\] 6 mg/mL•minute
Study NCT01563770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza extract
Description: 3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
Study NCT01563770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo capsules, twice daily for four consecutive weeks
Study NCT02907294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999 / 160 mg
Description: 2 capsule 80 mg x 8 days
Study NCT02907294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999 / 320 mg
Description: 4 capsule 80 mg x 8 days
Study NCT02907294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
Study NCT01334151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin LISPRO
Description: Single doses of: 0.15 U/kg
Study NCT01334151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human insulin
Description: Single doses of: 0.15 U/kg
Study NCT00129324 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lead Hazard Control Intervention
Description: Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
Study NCT00129324 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Injury Hazard Control Intervention
Description: Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
Study NCT03799250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Description: Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
Study NCT03799250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care
Study NCT01610180 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eltrombopag Olamine
Description: Initial dose : 50 mg/day for 14 days.~Next doses:~1. If platelet count \<60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~2. If platelet count >60000/µL and ≤200000/µL same dose for the next 14 days.~3. If platelet count >200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~4. If platelet count >400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is \<150000/µL, reinitiate therapy at a daily dose reduced by 25 mg.
Study NCT01838109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplement
Study NCT01111851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Description: a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
Study NCT01111851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 165 mg
Description: a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
Study NCT01111851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 250 mg
Description: a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
Study NCT01111851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (12-8-16-16 mg)
Description: Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
Study NCT01111851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (12-8-8-16 mg)
Description: Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
Study NCT01111851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
Study NCT01111851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0999
Description: I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)
Study NCT01372384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily
Study NCT03410173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine
Study NCT03410173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02701543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ranger Drug Eluting Balloon
Description: Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
Study NCT02701543 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In Pact Drug Eluting Balloon
Description: Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
Study NCT04360551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40mg
Description: Angiotensin Receptor Blocker (ARB)
Study NCT04360551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT03219242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caiman® device
Description: Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
Study NCT00960661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
Study NCT00960661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro
Description: titrated based on pre-meal glucose level; three times a day
Study NCT00960661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT00960661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00960661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin/ Glargine
Study NCT00960661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin/ Glargine
Study NCT02770547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Heat Thermotherapy
Description: Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
Study NCT02770547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Heat Thermotherapy
Description: Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
Study NCT00859378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented semiendoprosthesis
Description: Application of a cemented semiendoprosthesis (Basis, Smith \& Nephew)
Study NCT00859378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-cemented
Description: Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
Study NCT03134599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study NCT03134599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methafilcon A - Interozzo
Description: contact lens
Study NCT03134599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methafilcon A - CVI (CooperVision)
Description: contact lens
Study NCT03385811 — intervention group
Intervention type: OTHER
Intervention: no intervention, only questionnaires survey
Description: questionnaires survey
Study NCT02031497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink with sweeteners
Description: Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Study NCT02031497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drink with sweeteners
Description: Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Study NCT02031497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink without sweeteners
Description: Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Study NCT02031497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drink without sweeteners
Description: Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Study NCT03147716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enrollment Flyer
Description: Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
Study NCT03147716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enrollment Flyer
Description: Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
Study NCT03147716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testimonial Booklet
Description: Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
Study NCT03147716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teacher Endorsement
Description: Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
Study NCT03147716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Engagement Call
Description: This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
Study NCT02376270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pectin
Description: This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
Study NCT02376270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
Study NCT01375842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure \</= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
Study NCT03546530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: Interferon
Study NCT03546530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon+resveratrol
Description: Interferon+resveratrol
Study NCT01972620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of \~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
Study NCT02840695 — intervention group
Intervention type: DRUG
Intervention: bDMARD treatment
Description: Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
Study NCT01392534 — intervention group
Intervention type: DRUG
Intervention: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
Description: Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study NCT00918034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talaporfin sodium
Description: LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
Study NCT00918034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transurethral illumination with light emitting diodes
Description: A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
Study NCT00918034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement
Description: Placement of device in prostate urethra
Study NCT02162524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
Study NCT00861068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPM927/Lacosamide
Description: SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
Study NCT00861068 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets two times a day for 10 weeks
Study NCT03014778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Chlorhexidine gluconate 0.05%
Description: Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
Study NCT03014778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% Povidone iodine
Description: Washing vagina pre- operatively with 10% Povidone iodine
Study NCT02512471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
Study NCT02512471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
Study NCT03108547 — intervention group
Intervention type: OTHER
Intervention: Determination of scalp hair steroids
Study NCT00185744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-Operative Radiotherapy (IORT)
Description: single dose in the operating room after lumpectomy
Study NCT00185744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Study NCT00185744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Study NCT00185744 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Radiotherapy
Description: six and a half week treatment
Study NCT00185744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary Brachytherapy
Description: 5 day treatment
Study NCT00185744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated External Beam 3-D Conformal Radiotherapy
Description: 5 day treatment
Study NCT00185744 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic APBI
Description: 4 day treatment
Study NCT02735395 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing (SRP)
Description: SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.